News & Events
Read our recent press releases and follow Vascudyne’s newest advancements
September 18, 2025
Vascudyne Presented Bioengineered Heart Valve Innovation at HVBTE Conference
Exciting to share that Vascudyne’s leadership team presented scientific updates on our bioengineered tissue heart valve programs at the 10th Heart Valve Biology and Tissue Engineering conference, held at The Royal Society in London today.
The distinguished conference was hosted by Sir Magdi Yacoub, world-renowned heart surgeon, and Prof. Ajit Yoganathan, who also serves as a key advisor on our DOD-funded Congenital heart valve program.
CEO Dr. Zeeshan Syedain, Director of Congenital Heart Programs Prof. Robert Tranquillo, and Director of R&D Mariah McMahon presented three comprehensive presentations showcasing significant progress across our key initiatives:
🔬 Congenital pulmonary heart valve conduit development
🫀 Transcatheter heart valve advancement
🩺 Vascular clinical program expansion
Presenting at The Royal Society, alongside world-leading heart valve surgeons and scientists reinforces our position at the forefront of Pediatric heart valve innovation.
The enthusiastic reception from the global cardiovascular research community validates our mission to develop life-changing treatments for patients with congenital and acquired heart valve disease, supported by our strategic partnerships and US Department of Defense CDMRP funding.
#HeartValve #BioengineeredTissue #CongenitalHeart #MedicalInnovation #HVBTE2025 #RoyalSociety
HVBTE conference photo
Address
Social Media
These are investigational uses that have not been approved by any health authority. Safety and efficacy have not been established and there is no guarantee that pipeline products or investigational uses will receive approval from health authorities.
Copyright 2025 | Vascudyne, Inc.
